GlaxoSmithKline CEO Andrew Witty has said moving the European Medicines Agency (EMA) from London will cause “tremendous disruption.”
Witty is worried moving the EMA and its 900 staff from London to another European city post-Brexit will cause upheaval that affects the smooth running of the regulatory machinery.
The fate of EMA is one of many questions raised by the United Kingdom’s vote to leave the European Union. Politicians across Europe are lobbying for EMA to move to their country once the U.K. leaves the EU. And, faced with threats that foreign biopharma investment will fall if EMA leaves London, the U.K. is also pushing to retain the headquarters of the regulator even as it plans to sever its links to the EU.
Witty, like other pharma execs with major U.K. operations, wants EMA to stay in London. To make the case, Witty has branched out beyond the links between EMA and the U.K. regulator that others have played up. The CEO chose instead to focus on the best outcome for patients, which also happens to be his preferred result from a business perspective.
“A lot of staff are going to have to change positions,” Witty told Bloomberg Television. “Those who don’t leave have to relocate. This is a regulator who is keeping an eye on the health and safety of hundreds of millions of Europeans. You don’t want them with their eye off the ball.”
There is evidence the uncertainty created by Brexit is already affecting EMA. Talking to European politicians earlier this month, EMA Executive Director Guido Rasi said good candidates for jobs at the agency are withdrawing their applications, Regulatory Focus reports. Six employees resigned in the month following the Brexit vote. Rasi wants additional measures to support staff.
The uncertainty is likely to continue for some time. When asked about how the U.K. will handle drug approvals and other regulatory tasks post-Brexit, the politicians in charge of managing the process have given a range of noncommittal answers.
Some government politicians have proposed a Norway-style relationship that keeps the U.K. in the EU regulatory network. Others have shown a willingness to make a clean split. A middle-ground that sees the U.K. standardize its approval process with the EU in an attempt to avoid becoming a lower-priority market for drugmakers is also on the cards.
By Nick Paul Taylor
Source: Fierce Biotech
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.